Tremfya (guselkumab) is a biologic therapy that selectively blocks interleukin 23 (IL-23), a pro-inflammatory cytokine thought to play a major role in chronic immune-mediated diseases, including plaque psoriasis and psoriatic arthritis.

Tremfya is a fully human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of interleukin (IL)-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. By blocking interleukin 23, Tremfya inhibits the release of cytokines and chemokines that cause inflammation.

Tremfya is an interleukin-23 blocker indicated for the treatment of adult patients with:

• moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
• active psoriatic arthritis.

Tremfya was the first interleukin-23 blocker to be approved for the treatment of plaque psoriasis, and the first interleukin-23 blocker to be approved for psoriatic arthritis.
See Tremfya Approval History.

FDA Approved Interleukin-23 Blockers